期刊
IMMUNOTHERAPY
卷 4, 期 1, 页码 43-57出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.154
关键词
ATRA; cancer; exosome; fluorouracil; gemcitabine; immunotherapy; myeloid-derived suppressor cells; sildenafil; STAT3; sunitinib
类别
资金
- University of Burgundy
- Centre George-Francois Leclerc at Dijon (France)
- French Agence Nationale de la Recherche [ANR-10-PDOC-014-01]
- Institut National pour la Sante et al Recherche Medicate, Paris, France
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to efficiency of cancer immunotherapy. Several means of preventing MDSCs accumulation or inhibiting their immunosuppressive effect were recently discovered in cancer-bearing hosts, contributing to restoring antitumor immunity and consequently to control of tumor growth. In experimental tumor models, targeting MDSCs can enhance the effects of active or passive immunotherapy. While similar effects have not yet been noted in cancer-bearing patients, recent preclinical findings demonstrating that the selective toxicity of conventional chemotherapies such as gemcitabine and 5-fluorouracil on MDSCs might contribute to their anticancer effect provide impetus to pursue investigations to unravel novel therapeutics that target MDSCs in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据